Rational approach to discover multipotent anti-Alzheimer drugs

被引：232
|
作者：
Rosini, M
Andrisano, V
Bartolini, M
Bolognesi, ML
Hrelia, P
Minarini, A
Tarozzi, A
Melchiorre, C
机构：
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[2] Univ Bologna, Dept Pharmacol, I-40126 Bologna, Italy
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 02期
关键词：
D O I：
10.1021/jm049112h
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The coupling of two different pharmacophores, each endowed with different biological properties, afforded the hybrid compound lipocrine (7), whose biological profile was markedly improved relative to those of prototypes tacrine and lipoic acid. Lipocrine is the first compound that inhibits the catalytic activity of AChE and AChE-induced amyloid-beta aggregation and protects against reactive oxygen species. Thus, it emerged as a valuable pharmacological tool to investigate Alzheimer's disease and as a promising lead compound for new anti-Alzheimer drugs.
引用
收藏
页码：360 / 363
页数：4
相关论文
共 50 条
  • [1] Naturally occurring multipotent anti-Alzheimer's agents
    Zhang, Hong-Yu
    Yang, Da-Peng
    Ji, Hong-Fang
    EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (03) : 269 - 277
  • [2] Clinical pharmacology of anti-Alzheimer drugs
    Pettenati, C
    Annicchiarico, R
    Caltagirone, C
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (06) : 659 - 672
  • [3] Developing effective anti-Alzheimer's drugs
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) : 735 - 735
  • [4] Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase
    Tan, Yan
    Zhang, Qi
    Wong, Steven G.
    Hua, Qian
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (05) : 549 - 557
  • [5] POTENTIAL BIOLOGICAL TARGETS FOR ANTI-ALZHEIMER DRUGS
    ALLAIN, H
    BELLIARD, S
    DECERTAINES, J
    BENTUEFERRER, D
    BUREAU, M
    LACROIX, P
    DEMENTIA, 1993, 4 (06): : 347 - 352
  • [6] Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates
    Turkez, Hasan
    Cacciatore, Ivana
    Arslan, Mehmet Enes
    Fornasari, Erika
    Marinelli, Lisa
    Di Stefano, Antonio
    Mardinoglu, Adil
    BIOMOLECULES, 2020, 10 (05)
  • [7] Cognition enhancers, anti-Alzheimer and neuroprotective drugs - Introduction
    Scriabine, A
    CNS DRUG REVIEWS, 2000, 6 : 1 - 2
  • [8] Factors associated with persistence to anti-alzheimer drugs in France
    Pinet, Marion
    Pariente, Antoine
    Merliere, Yvon
    Moride, Yola
    Moore, Nicholas
    Fourrier-Reglat, Annie
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S34 - S35
  • [9] Experimental and clinical methods in the development of anti-Alzheimer drugs
    Allain, H
    Bentue-Ferrer, D
    Zekri, O
    Schück, S
    Lebreton, S
    Reymann, JM
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1998, 12 (01) : 13 - 29
  • [10] The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis
    Sugimoto, Hachiro
    CHEMICO-BIOLOGICAL INTERACTIONS, 2008, 175 (1-3) : 204 - 208
12345